ARTICLE | Company News
Pfizer gastrointestinal news
March 17, 2014 7:00 AM UTC
The U.S. District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue of U.S. Patent No. RE44048, which covers pain and autoimmune drug Celebrex celecoxib, for obviousness-type double patenting. The U.S. Patent and Trademark Office (PTO) reissued the patent in March 2013, extending the original May 30, 2014, expiration date to Dec. 2, 2015. Pfizer said it plans to immediately appeal the court's decision and pursue "all available remedies." The product is a cyclooxygenase-2 (COX-2) inhibitor (see BioCentury, March 18, 2013). ...